Alexion Soliris Label Mentions QOL Results Despite Reviewer Misgivings
This article was originally published in Pharmaceutical Approvals Monthly
Labeling for Alexion's Soliris (eculizumab) includes a statement regarding improved health-related quality of life despite FDA reviewer concerns about adequacy of the QOL assessment
You may also be interested in...
Keeping Track: 2021’s First Novel Approvals Go To HIV And Heart Failure Therapies Opdivo Starts Year With A Bang
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.